- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
News Archive
miRagen Therapeutics and t2cure Sign Licensing Agreement for microRNA Target Implicated in Vascular Disease11.30.2010
Agreement expands miRagen’s research and development, intellectual property in the field of microRNA-based therapeutics
t2cure’s Cellular Therapeutic Receives Orphan Drug Designation 06.24.2010
Frankfurt, Germany, June 24, 2010 – t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of...
t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA05.25.2010
FRANKFURT, May 25, 2010 /PRNewswire/ -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the...
Stem Cell Company t2cure Appoints Dr Petra Rueck and Susanne Knigge as Co-CEOs01.11.2010
Frankfurt, Germany, January 11, 2010 – t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based therapies, announced today that it has appointed Dr. Petra Rueck and Mrs. Susanne Knigge to Co-CEO’s, effective...
t2cure to present at Science4Life fair10.16.2009
t2cure will present at the 2nd Science4Life fair in the Jahrhunderthalle Höchst in Frankfurt on October 22, 2009. Over 80 companies in the Life Science and Chemistry industry across Germany will present to a broad audience. The founders’...